VERSINO, Elisabetta
VERSINO, Elisabetta
SCIENZE CLINICHE E BIOLOGICHE
A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b
2006-01-01 A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
A systematic review and meta-analysis indicates long-term risk of chronic and end-stage kidney disease after preeclampsia.
2019-01-01 Covella B; Vinturache AE Cabiddu G; Attini R; Gesualdo L; Versino E; Piccoli GB
Assessing treatment response to immunomodulatory drugs for ms: a single active mri scan after 6 months of treatment is the best indicator of persisting disease activity
2005-01-01 L. DURELLI; E. VERDUN; P. BARBERO; M. CLERICO; B. FERRERO; E. VERSINO; G. GIULIANI; E. MONTANARI; THE OPTIMS STUDY GROUP
Best indicator of persisting disease activity
2005-01-01 L. DURELLI; E. VERDUN; P. BARBERO; M. CLERICO; B. FERRERO; E. VERSINO; G. GIULIANI; E. MONTANARI; AND THE OPTIMS STUDY GROUP
The best indication to early treat the clinically isolated syndrome based on the clinical onset. A Cochrane analysis
2009-01-01 Clerico, M; Versino, E; Contessa, G; Ripellino, P; Palace, J; Tintore, M; Durelli, L
Chronic kidney disease: The complex history of the organization of long-term care and bioethics. why now, more than ever, action is needed
2019-01-01 Versino E., Piccoli G.B.
Clinical and laboratory tolerability evaluation of treatment with high-dose interferon beta-1b (500mcg every-other-day, subcutaneously) in ms patients.
2003-01-01 A. PIPIERI; P. BARBERO; M. CLERICO; E. VERDUN; E. VERSINO; A. CUCCI; E. PUCCI; E. CARTECHINI; L. MANNESCHI; G. GIULIANI; E. MONTANARI; L. DURELLI
Clinically isolated syndrome: when to treat? A Cochrane analysis
2009-01-01 Marinella Clerico; Elisabetta Versino; Giulia Contessa; Jacqueline Palace; Mar Tintore'; Luca Durelli
Comparision of a biological (mxa protein level) and an mri treatment response indicator for interferon beta therapy in multiple sclerosis
2006-01-01 G. CONTESSA; M. CLERICO; P. BARBERO; B. FERRERO; A. RICCI; E. VERSINO; G. GIULIANI; E. MONTANARI; L. DURELLI; FOR THE OPTIMS STUDY GROUP
Compulsory Psychiatric Admissions in an Italian Urban Setting: Are They Actually Compliant to the Need for Treatment Criteria or Arranged for Dangerous Not Clinical Condition?.
2019-01-01 Oliva F; Ostacoli L; Versino E; Portigliatti Pomeri A; Furlan PM; Carletto S; Picci RL.
Consumo di ecstasy tra i diciottenni della Regione Piemonte convocati per la visita di leva
1999-01-01 E. VERSINO; IPPOLITO R; MITOLA B; NICOLAZZO M; SILIQUINI R
Correlation of anti-interferon beta neutralising antobodies with clinical response and mri activity in the INCOMIN (independent comparison of interferon) trial.
2003-01-01 P. BARBERO; E. VERDUN; M. CLERICO; A. PIPIERI; A. RICCI; M. BERGUI; E. VERSINO; G. ANTONELLI; M. ZAFFARONI; A. GHEZZI; E. MONTANARI; L. DURELLI; AND INCOMIN STUDY GROUP
COVID-19 Vaccine Hesitancy in Patients on Dialysis in Italy and France
2021-01-01 Bianchi S, Torreggiani M, Chatrenet A ,Fois A , Mazé B , Njandjo L, Bianco G, Lepori L, Pili A ,Michel PA, Sileno G, Arazzi M, Esposito V, Pani A , Versino E, Esposito C, Fessi H, Cabiddu G, Piccoli GB
Cytokines and Chemokine mRNA in perpheral blood of multiple sclerosis patients correlates with treatment response and interferon beta dose
2008-01-01 Giulia Contessa; Marinella Clerico; Angele Cucci; Chiara Rivoiro; Pierangelo Barbero; Bruno Ferrero; Elisabetta Versino; Cinzia Ferrero; Paolo Ripellino; Luca Durelli
Deaths attributable to tobacco smoking in Italy
2008-01-01 Mathis F; Vigna-Taglianti F; Migliardi A; Versino E; Faggiano F
Decennial trends of social differentials in smoking habits in Italy
2001-01-01 F. FAGGIANO; E. VERSINO; P. LEMMA
I determinanti delle disuguaglianze sociali nella salute in Italia
2000-01-01 FAGGIANO F; RENGA G; E. VERSINO
[Determinants of social inequalities in health in Italy]
2000-01-01 FAGGIANO F ;RENGA G ;VERSINO E
Diet as a system: an observational study investigating a multi-choice system of moderately restricted low-protein diets
2016-01-01 Piccoli, Giorgina Barbara; Nazha, Marta; Capizzi, Irene; Vigotti, Federica Neve; Scognamiglio, Stefania; Consiglio, Valentina; Mongilardi, Elena; Bilocati, Marilisa; Avagnina, Paolo; Versino, Elisabetta
Differenze di genere alla presa in carico al SerT: risultati dallo studio VEdeTTE
2004-01-01 Vigna-Taglianti F; Versino E; Burroni P; Beccaria F; Garneri M; Rotelli M; Mathis F; Bertuccio P
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b | 2006 | A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP | |
| A systematic review and meta-analysis indicates long-term risk of chronic and end-stage kidney disease after preeclampsia. | 2019 | Covella B; Vinturache AE Cabiddu G; Attini R; Gesualdo L; Versino E; Piccoli GB | |
| Assessing treatment response to immunomodulatory drugs for ms: a single active mri scan after 6 months of treatment is the best indicator of persisting disease activity | 2005 | L. DURELLI; E. VERDUN; P. BARBERO; M. CLERICO; B. FERRERO; E. VERSINO; G. GIULIANI; E. MONTANARI; THE OPTIMS STUDY GROUP | |
| Best indicator of persisting disease activity | 2005 | L. DURELLI; E. VERDUN; P. BARBERO; M. CLERICO; B. FERRERO; E. VERSINO; G. GIULIANI; E. MONTANARI; AND THE OPTIMS STUDY GROUP | |
| The best indication to early treat the clinically isolated syndrome based on the clinical onset. A Cochrane analysis | 2009 | Clerico, M; Versino, E; Contessa, G; Ripellino, P; Palace, J; Tintore, M; Durelli, L | |
| Chronic kidney disease: The complex history of the organization of long-term care and bioethics. why now, more than ever, action is needed | 2019 | Versino E., Piccoli G.B. | |
| Clinical and laboratory tolerability evaluation of treatment with high-dose interferon beta-1b (500mcg every-other-day, subcutaneously) in ms patients. | 2003 | A. PIPIERI; P. BARBERO; M. CLERICO; E. VERDUN; E. VERSINO; A. CUCCI; E. PUCCI; E. CARTECHINI; L. MANNESCHI; G. GIULIANI; E. MONTANARI; L. DURELLI | |
| Clinically isolated syndrome: when to treat? A Cochrane analysis | 2009 | Marinella Clerico; Elisabetta Versino; Giulia Contessa; Jacqueline Palace; Mar Tintore'; Luca Durelli | |
| Comparision of a biological (mxa protein level) and an mri treatment response indicator for interferon beta therapy in multiple sclerosis | 2006 | G. CONTESSA; M. CLERICO; P. BARBERO; B. FERRERO; A. RICCI; E. VERSINO; G. GIULIANI; E. MONTANARI; L. DURELLI; FOR THE OPTIMS STUDY GROUP | |
| Compulsory Psychiatric Admissions in an Italian Urban Setting: Are They Actually Compliant to the Need for Treatment Criteria or Arranged for Dangerous Not Clinical Condition?. | 2019 | Oliva F; Ostacoli L; Versino E; Portigliatti Pomeri A; Furlan PM; Carletto S; Picci RL. | |
| Consumo di ecstasy tra i diciottenni della Regione Piemonte convocati per la visita di leva | 1999 | E. VERSINO; IPPOLITO R; MITOLA B; NICOLAZZO M; SILIQUINI R | |
| Correlation of anti-interferon beta neutralising antobodies with clinical response and mri activity in the INCOMIN (independent comparison of interferon) trial. | 2003 | P. BARBERO; E. VERDUN; M. CLERICO; A. PIPIERI; A. RICCI; M. BERGUI; E. VERSINO; G. ANTONELLI; M. ZAFFARONI; A. GHEZZI; E. MONTANARI; L. DURELLI; AND INCOMIN STUDY GROUP | |
| COVID-19 Vaccine Hesitancy in Patients on Dialysis in Italy and France | 2021 | Bianchi S, Torreggiani M, Chatrenet A ,Fois A , Mazé B , Njandjo L, Bianco G, Lepori L, Pili A ,Michel PA, Sileno G, Arazzi M, Esposito V, Pani A , Versino E, Esposito C, Fessi H, Cabiddu G, Piccoli GB | |
| Cytokines and Chemokine mRNA in perpheral blood of multiple sclerosis patients correlates with treatment response and interferon beta dose | 2008 | Giulia Contessa; Marinella Clerico; Angele Cucci; Chiara Rivoiro; Pierangelo Barbero; Bruno Ferrero; Elisabetta Versino; Cinzia Ferrero; Paolo Ripellino; Luca Durelli | |
| Deaths attributable to tobacco smoking in Italy | 2008 | Mathis F; Vigna-Taglianti F; Migliardi A; Versino E; Faggiano F | |
| Decennial trends of social differentials in smoking habits in Italy | 2001 | F. FAGGIANO; E. VERSINO; P. LEMMA | |
| I determinanti delle disuguaglianze sociali nella salute in Italia | 2000 | FAGGIANO F; RENGA G; E. VERSINO | |
| [Determinants of social inequalities in health in Italy] | 2000 | FAGGIANO F ;RENGA G ;VERSINO E | |
| Diet as a system: an observational study investigating a multi-choice system of moderately restricted low-protein diets | 2016 | Piccoli, Giorgina Barbara; Nazha, Marta; Capizzi, Irene; Vigotti, Federica Neve; Scognamiglio, Stefania; Consiglio, Valentina; Mongilardi, Elena; Bilocati, Marilisa; Avagnina, Paolo; Versino, Elisabetta | |
| Differenze di genere alla presa in carico al SerT: risultati dallo studio VEdeTTE | 2004 | Vigna-Taglianti F; Versino E; Burroni P; Beccaria F; Garneri M; Rotelli M; Mathis F; Bertuccio P |